News


The Francis Crick Institute Renews the Research License Agreement with ExpreS2ion Biotechnologies

Horsholm, Denmark, June 26, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the Francis Crick Institute, London, United Kingdom, has agreed to amend the Research License Agreement about ExpreS2ion’s proprietary ExpreS2 expression system for another year. The Research License Agreement…


“Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies”

The ExpreS2 system was used for the production of recombinant PvDBP_RII (SalI) protein for ELISA-based assays in the article “Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies” Abstract BACKGROUND. Plasmodium vivax is the most widespread human malaria geographically; however, no effective vaccine exists. Red blood cell invasion by…


ExpreS2ion’s Chief Executive Officer, Dr. Steen Klysner, Speaks at Investordagen in Aarhus, Denmark – June 13

Horsholm, Denmark, June 8, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that its Chief Executive Officer, Dr. Steen Klysner, is speaking at Investordagen in Aarhus, Denmark on June 13th, 2017. The event is an arrangement by Dansk Aktionærforening, with expected…


“Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal ‘C-tag’”

The ExpreS2 system was used in the production of  the recombinant protein produced in the study “Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal ‘C-tag’” Abstract Development of bespoke biomanufacturing processes remains a critical bottleneck for translational studies, in particular when…


Interview with CEO Steen Klysner in Erhverv Nordsjælland

Expres2ion Biotechnologies is mentioned in the Danish newspaper Erhverv Nordsjælland. The article includes an interview with CEO Sten Klysner. The article can be seen on http://www.e-pages.dk/erhvervnordsjaelland/36/ A small version of the article is available here: Article (pdf)


ExpreS2ion’s Chief Scientific Officer, Dr. Wian de Jongh, to Speak at ISBiotech 7th Spring Meeting in Washington D.C. – March 6-8

Horsholm, Denmark, February 16, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that its Chief Scientific Officer, Dr. Willem Adriaan (“Wian”) de Jongh, is speaking at the ISBiotech 7th Spring Meeting in Washington D.C., USA, on March 6th, 2017, presenting under…


ExpreS2ion’s Chief Scientific Officer, Dr. Wian de Jongh, is Appointed Affiliated Associate Professor at the Technical University of Denmark

Horsholm, Denmark, February 14, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that its Chief Scientific Officer, Dr. Willem Adriaan (“Wian”) de Jongh, is appointed the honorary position of affiliated associate professor at the Technical University of Denmark (“DTU”). The position…


The ExpreS2 system used in a new study published in Vaccine “Comparison of functional assays used in the clinical development of a placental malaria vaccine”

The article “Comparison of functional assays used in the clinical development of a placental malaria vaccine” was recently published in Vaccine. Abstract BACKGROUND: Malaria in pregnancy is associated with significant morbidity in pregnant women and their offspring. Plasmodium falciparum infected erythrocytes (IE) express VAR2CSA that mediates binding to chondroitin sulphate A…